Combination therapy

Patent metadata

Field	Value
Publication number	US-10548894-B2
Application number	US-201815875031-A
Country	US
Kind code	B2
Filing date	Jan 19, 2018
Priority date	Mar 21, 2013
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

First claim

The invention claimed is:

1. A method for treating a patient suffering from melanoma, which comprises:
(a) administering to the patient a therapeutically effective amount of a B-Raf inhibitor as a monotherapy, or a pharmaceutically acceptable salt thereof, until the patient exhibits disease progression;
(b) obtaining a tumor sample from the patient after disease progression and detecting a genetic alteration in one or more genes selected from the group consisting of BRAF, CRAF, MAP2K1, MAPK2, NRAS, KRAS HRAS and EGFR; and
(c) administering a drug combination therapy comprising a compound of formula (I):

and a Mek 1/2 inhibitor which is Compound B:

2. The method of claim 1 , wherein the B-Raf inhibitor in step (a) is a compound of formula (I).

3. The method of claim 1 , wherein the gene is BRAF.

4. The method of claim 1 , wherein the genetic alteration results from amplification of the one or more genes, mutations in the one or more genes, or loss of the one or more genes' activity.

5. The method of claim 1 , wherein the genetic alteration results from a mutation in one or more genes.

6. The method of claim 5 , wherein the one or more genes is BRAF.

7. The method of claim 6 , wherein the mutation is a V600 mutation in BRAF.

8. The method of claim 7 , wherein the V600 mutation in BRAF is a V600E mutation or a V600K mutation.

9. The method of claim 7 , wherein the V600 mutation in BRAF is a V600E mutation.

10. The method of claim 1 , wherein disease progression is evaluated using RECIST criteria.

11. The method of claim 1 , wherein the B-Raf inhibitor in step (a) is administered continuously.

12. The method of claim 1 , wherein the B-Raf inhibitor in step (a) is administered intermittently.

13. The method of claim 1 , wherein the compound of formula (I) in step (c) is administered continuously.

14. The method of claim 1 , wherein the compound of formula (I) in step (c) is administered intermittently.

15. The method of claim 1 , wherein the B-Raf inhibitor in step (a) is administered orally.

16. The method of claim 1 , wherein the compound of formula (I) and Compound B in step (c) are each administered orally.

17. The method of claim 1 , wherein the B-Raf inhibitor in step (a) is administered at a dose of from 150 mg to 600 mg/day.

18. The method of claim 1 , wherein the compound of formula (I) in step (c) is administered at a dose of from 150 mg to 600 mg/day.

19. The method of claim 1 , wherein the compound of formula (I) in step (c) is administered at a dose of 450 mg/day.

20. The method of claim 1 , wherein Compound B in step (c) is administered at a dose of from 15 mg to 60 mg twice daily.

21. The method of claim 20 , wherein Compound B in step (c) is administered at a dose of 45 mg twice daily.

22. The method of claim 21 , wherein the two doses of Compound B are administered 12 hours apart.

23. The method of claim 1 , wherein the compound of formula (I) and Compound B are administered during a 21 day cycle.

24. The method of claim 1 , wherein the melanoma is a locally advanced or metastatic melanoma.

25. The method of claim 1 , wherein the melanoma is an unresectable stage III melanoma or a stage IIIC to IV metastatic melanoma.

26. The method of claim 1 , wherein prior to step (a), the patient is nave to a BRAF inhibitor.

Assignees

• Array Biopharma Inc

Inventors

• Caponigro Giordano
• Stuart Darrin
• De Parseval Laure

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title